Moderna stock declined due to lower demand for COVID-19 vaccines, but maintains strong product pipeline

From Nasdaq, Inc.: 2025-03-20 08:45:00

Moderna (NASDAQ: MRNA) saw a sharp decline in stock value after projections of sustained demand for COVID-19 vaccines failed to materialize. Despite this, the company maintains strength in its product pipeline and financials, with $9.5 billion in cash and investments. Revenue fell from $19.3 billion in 2022 to $3.2 billion in 2024, with a net loss of $3.6 billion last year. Moderna aims to expand its mRNA technology beyond COVID-19, with upcoming vaccine candidates for norovirus and cytomegalovirus, as well as a personalized cancer vaccine in phase 3 trials. Wall Street analysts predict continued losses for the company.



Read more at Nasdaq, Inc.: 4 Things You Need to Know if You Buy Moderna Stock Today